Stryker Corporation $SYK Shares Newly Bought by Anderson Hoagland & Co.

Key Points

• Anderson Hoagland & Co. bought a new Stryker position of 9,966 shares worth approximately $2.745 million in the third quarter. Institutional investors and hedge funds collectively own 77.09% of SYK.
• Stryker insiders sold 351,267 shares worth about $118.2 million over the past 90 days, including Director Ronda E. Stryker’s $100.8 million sale.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $369 price target. The company also reported quarterly EPS of $3.69, revenue of $6.59 billion, and declared a quarterly dividend of $0.88 per share.

Anderson Hoagland & Co. purchased a new position in Stryker Corporation (NYSE:SYK - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,966 shares of the medical technology company's stock, valued at approximately $2,745,000.

Several other institutional investors have also made changes to their positions in SYK. Brookmont Capital Management raised its holdings in shares of Stryker by 7.1% during the third quarter. Brookmont Capital Management now owns 1,112 shares of the medical technology company's stock worth $306,000 after acquiring an additional 74 shares in the last quarter. Sowell Financial Services LLC lifted its stake in Stryker by 31.5% in the third quarter. Sowell Financial Services LLC now owns 1,730 shares of the medical technology company's stock valued at $476,000 after acquiring an additional 414 shares during the last quarter. Bright Financial Advisors Inc. grew its position in Stryker by 2.0% in the third quarter. Bright Financial Advisors Inc. now owns 23,870 shares of the medical technology company's stock worth $6,574,000 after acquiring an additional 476 shares in the last quarter. Gibbs Wealth Management bought a new stake in Stryker in the third quarter worth approximately $240,000. Finally, Tectonic Advisors LLC grew its position in Stryker by 69.1% in the third quarter. Tectonic Advisors LLC now owns 4,109 shares of the medical technology company's stock worth $1,132,000 after acquiring an additional 1,679 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares of the company's stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Raymond James Financial set a $370.00 price objective on shares of Stryker in a report on Friday, July 31st. Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Finally, Barclays upgraded Stryker to a "strong-buy" rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $369.00.

Stryker Trading Up 0.2%

Shares of NYSE:SYK opened at $307.65 on Friday. The company has a market cap of $118.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78. The stock's 50-day moving average is $295.23 and its 200-day moving average is $311.93. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the company posted $3.13 earnings per share. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.